Watch ISCO. Know when insiders buy.
One email the day a filing lands. Free.
ISCO
International Stem Cell CORP
0.32
−0.06 −15.79%
USD · close Sep 15
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
75
PASS · insiders 49, shorts 100
Insiders, 90 days
−$10K
net selling · 0 buys, 1 sell
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $2.6MP/E —DIV YIELD —FCF YIELD 13.00%REV TTM $9.5M +3.4%NET INCOME −$582KNET CASH —52W 0.12 – 0.51SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $2.7M | +9.3% | 54.5% | −$35K | −$71K | −155.0% | -0.01 | $167K | $7K | $160K | Aug 13 |
| Q1 2026 · Mar 31 | $2.3M | +8.7% | 58.8% | −$190K | −$220K | — | -0.03 | $121K | $23K | $98K | Aug 13 |
| Q4 2025 · Dec 31derived | $2.2M | −11.9% | 50.5% | −$313K | −$348K | −3263.6% | -0.04 | $32K | $3K | $29K | Mar 30 |
| Q3 2025 · Sep 30 | $2.4M | +8.7% | 55.8% | $94K | $57K | — | 0.00 | $49K | $3K | $46K | Nov 13 |
| Q2 2025 · Jun 30 | $2.4M | +5.0% | 62.1% | $167K | $129K | +8.4% | 0.01 | −$300K | $32K | −$332K | Aug 13 |
| Q1 2025 · Mar 31 | $2.1M | +0.0% | 53.4% | −$215K | −$256K | — | -0.03 | $227K | $5K | $222K | Aug 13 |
| Q4 2024 · Dec 31derived | $2.4M | +29.5% | 59.5% | $51K | $11K | — | 0.00 | −$74K | $1K | −$75K | Mar 30 |
| Q3 2024 · Sep 30 | $2.2M | +10.4% | 55.3% | −$90K | −$125K | — | -0.02 | $257K | $37K | $220K | Nov 13 |
| Q2 2024 · Jun 30 | $2.3M | — | 60.8% | $149K | $119K | — | 0.01 | $23K | $120K | −$97K | Nov 13 |
| Q1 2024 · Mar 31 | $2.1M | — | 58.3% | −$178K | −$214K | — | -0.03 | −$193K | $8K | −$201K | Nov 13 |
| Q4 2023 · Dec 31derived | $1.9M | — | 54.3% | −$424K | −$458K | — | -0.04 | $161K | $0 | $161K | Mar 28 |
| Q3 2023 · Sep 30 | $2M | — | 60.4% | −$97K | −$131K | — | -0.02 | $62K | $14K | $48K | Nov 13 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $9.1M | 55.7% | −$267K | −$418K | -4.6% | -0.05 | $8K | $43K | −$35K | — | — |
| FY2024 · to Dec 31 | $9.1M | 58.6% | −$68K | −$209K | -2.3% | -0.03 | $13K | $166K | −$153K | — | — |
| FY2023 · to Dec 31 | $7.8M | 59.2% | −$663K | −$131K | -1.7% | -0.02 | $929K | $80K | $849K | — | — |
| FY2022 · to Dec 31 | $8.2M | 60.0% | −$183K | −$331K | -4.0% | -0.04 | $332K | $1K | $331K | — | — |
| FY2021 · to Dec 31 | $7.2M | 59.1% | −$1.9M | −$899K | -12.5% | -0.11 | −$1.3M | $23K | −$1.3M | — | — |
| FY2020 · to Dec 31 | $7.1M | 61.0% | −$2.8M | −$2.7M | -38.2% | -0.36 | −$341K | $28K | −$369K | — | — |
Every number comes from International Stem Cell CORP's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.